Q-omics provides the consensus-scored VPS54 profile across patient tissues and cancer cell-line models. VPS54 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, VPS54 is differentially expressed in 15, with the highest sampling consensus in LIHC. Additionally, VPS54 RNA expression shows 20,741 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where VPS54 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VPS54 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VPS54 survival associations across molecular data types. VPS54 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (11) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VPS54 RNA expression–survival associations across cancer types. High VPS54 expression shows unfavorable associations in ACC, LGG, KICH, LIHC and CESC, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for VPS54 RNA expression.
This table summarizes VPS54 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for VPS54. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VPS54 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, BLCA, COAD and CHOL. The LIHC box plot shows higher VPS54 RNA expression in tumor versus normal tissue (log2 FC = +1.185, t-test p < 0.001).
This table shows molecular features associated with VPS54 in patient tissues and cancer cell lines. In patient samples, VPS54 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, VPS54 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
